April 6, 2005 — The U.S. Food and Drug Administration (FDA) announced in January revisions to safety labeling to advise healthcare professionals of the following changes: use of darbepoetin alfa ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...
THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...
LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 ÎĽg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...
LAS VEGAS—Switching anemic pre-dialysis chronic kidney disease (CKD) from darbepoetin to epoetin is associated with longer dosing intervals and lower drug costs, and hemoglobin levels are maintained ...
THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...
Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN No significant financial relationships to disclose. This ...
Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...
A federal judge approved a $762 million settlement Wednesday in a case involving Amgen's off-label promotion of darbepoetin alfa (Aranesp), an anemia drug. The biotech drug giant pled guilty Tuesday ...
A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results